Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2021 Jun;103(6):404-407.
doi: 10.1016/j.contraception.2021.01.007. Epub 2021 Jan 18.

Timing and efficacy of mifepristone pretreatment for medical management of early pregnancy loss

Affiliations
Randomized Controlled Trial

Timing and efficacy of mifepristone pretreatment for medical management of early pregnancy loss

Anne N Flynn et al. Contraception. 2021 Jun.

Abstract

Objectives: To determine the time interval between mifepristone and misoprostol administration associated with the most efficacious early pregnancy loss (EPL) management.

Study design: We performed a secondary analysis of a randomized trial. Participants with EPL were instructed to take 200 mg oral mifepristone followed by 800 mcg vaginal misoprostol 24 hours later. The primary outcome was gestational sac expulsion at the first follow-up visit (1-4 days after misoprostol use) after a single dose of misoprostol and no additional intervention within 30 days after treatment. Despite specification of drug timing, participants used the medication over a range of time. We graphed sliding average estimates of success and assessed the proportion of treatment successes over time to define timing interval cohorts for analysis. We used multivariable generalized linear regression to assess the association between time interval and success.

Results: Of 139 eligible participants, 70 (50.4%) self-administered misoprostol before 24 hours, and 69 (49.6%) at or after 24 hours. We defined the following time intervals: 0 to 6 hours (n = 22); 7 to 20 hours (n = 29); and 21 to 48 hours (n = 88). Success occurred in 96.6% of the 7- to 20-hour cohort compared to 54.6% and 87.5% of the cohorts self-administering misoprostol earlier or later, respectively. When adjusting for race, gestational age, diagnosis, bleeding at presentation, insurance status, and enrollment site, participants administering misoprostol between 0 and 6 hours (adjusted risk ratio 0.58, 95% CI 0.40-0.85) and 21 to 48 hours (adjusted risk ratio 0.91, 95% CI 0.72-0.99) had a lower risk of success when compared to participants administering 7 to 20 hours after mifepristone.

Conclusions: These data suggest that medical management of EPL has the highest likelihood of success when misoprostol is self-administered 7 to 20 hours after mifepristone.

Implications: These preliminary data suggest that patients have the highest likelihood of success when misoprostol is taken between 7 and 20 hours after mifepristone. In contrast with medical abortion, simultaneous medication administration may not be as effective as delayed. Future research is needed to confirm the optimal medication time interval.

Keywords: Early pregnancy loss; Medical management; Mifepristone; Miscarriage.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest: Dr Schreiber has received consulting fees from Danco laboratories. No other potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.
A Locally Weighted Scatterplot Smoothing (LOWESS) curve for early pregnancy loss treatment success by mifepristone and misoprostol administration time interval. Dots indicate observed treatment success (1) or failure (0). The solid line is a sliding average estimate of the probability of treatment success.

Similar articles

Cited by

References

    1. Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990–2008. Natl Vital Stat Rep 2012;60(7):1–21. - PubMed
    1. Trinder J, Brocklehurst P, Porter R, Read M, Vyas S, Smith L. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ 2006;332(7552):1235–40. - PMC - PubMed
    1. Schreiber CA, Creinin MD, Atrio J, Sonalkar S, Ratcliffe SJ, Barnhart KT. Mifepristone pretreatment for the medical management of early pregnancy loss. N Engl J Med 2018;378(23):2161–70. - PMC - PubMed
    1. Prager S, Dalton V, Allen RH, American College of Obstetricians and Gynecologists’ Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 200: early pregnancy loss. Obstet Gynecol 2018;132(5):e197–207. - PubMed
    1. Gemzell-Danielsson K, Bygdeman M, Aronsson A. Studies on uterine contractility following mifepristone and various routes of misoprostol. Contraception 2006;74(1):31–5. - PubMed

Publication types